Zalicus Inc. and Epirus Biopharmaceuticals, Inc. agreed that Zalicus stockholders will own 19% of the combined company post-merger. In addition, Dr. Mark H.N. Corrigan will serve as chairman of the company's board of directors, which will have representatives from both the existing Epirus and Zalicus boards.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 26 | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- EPRSQ Stock
- News EPIRUS Biopharmaceuticals, Inc.
- Epirus Biopharmaceuticals, Inc. Appoints Mark H.N. Corrigan to Board of Directors